randomized comparative trial of doxil vs. bleomycin and vincristine in the treatment of aids-related ks.

NLM AIDSLINE Randomized comparative trial of DOXIL vs. Bleomycin and Vincristine in the treatment of AIDS-Related KS. Stewart S; Jablonowski H; Goebel FD; L'Age M; Spittle M; Luthy R;
September 30, 1997

Int Conf AIDS. 1996 Jul 7-12;11(Program Supplement):27 (abstract no. 241 patients with HIV related Kaposi's Sarcoma (KS) were randomized to receive six 3-weekly cycles of either BV-Bleomycin, 15 mg/m(2) and Vincristine 2 mgs (120 patients)or DOXIL-20 mg/m(2) (121 patients). Both groups were well matched for prognostic factors: according to ACTG criteria, "Poor Risks KS" was seen in 57 (55.9%) of BV and 66 (56.9%) of DOXIL patients, Poor Immune Status" in 88 (86.3%) of BV and 103 (88.8%) of DOXIL patients and "Systemic Symptoms" in 42 (41.2%) of BV and 48 41.4%) of DOXIL patients. 57 (55.9%) of BV and 57 (49.1%) of DOXIL patients had a mean CD4=50 x 10(6)/L one hundred and two of the BV patients and 116 of the DOXIL were assessable for response and toxicity. KS response was assessed according to ACTG criteria and treatment intention. Patients who received DOXIL had a higher response rate than those receiving the BV combination - 7 (5.8%) CR and 63 (52.1%) PR versus 1 (0.8%) CR and 27 22.5%) PR (P-value less than 0.001). The mean time to response was shorter in the DOXIL arm - 48.8 versus 61.4 days (p is less than or equal to 0.009). Although DOXIL was better tolerated than BV with 15.7% versus 23.3% nausea/vomiting, 3.3% versus 8.3% alopecia and 8.3% versus 25.8% neuropathy it was more myelosuppressive; 76.0% versus 56.6% of patients had a neutrophil count less than 1.5 x 10(9)/l during treatment. Conclusions: DOXIL is recommended as first-line chemotherapy for HIV-related KS. AIDS-Related Opportunistic Infections/DRUG THERAPY Antineoplastic Agents, Combined/THERAPEUTIC USE *Sarcoma, Kaposi's/DRUG THERAPY

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 HIV messages should include MSM Stock-outs must be top of agenda TEXAS: Free HIV Testing CALIFORNIA: Entertainment AIDS Alliance (EAA) Presents 11th Annual Wine and Wisdom Fundraiser NORTH CAROLINA: ALFA Offers Free Community Health Educator Training in Hickory CALIFORNIA: Over Half of People Living with AIDS in San Francisco Are Aged 50 or Older THAILAND; UNITED STATES: HIV Drug Can Also Protect Injection Drug Users INDONESIA: Growing HIV/AIDS Awareness in Indonesia's Papua Region UNITED STATES: Many Young Americans Unaware They're Infected with HIV Board to Vote on Condoms in Boston Schools CALIFORNIA: Entertainment AIDS Alliance (EAA) Presents 11th Annual Wine and Wisdom Fundraiser CALIFORNIA: Over Half of People Living with AIDS in San Francisco Are Aged 50 or Older INDONESIA: Growing HIV/AIDS Awareness in Indonesia's Papua Region New Analysis of World's Premier AIDS Conference Finds Poor Coverage of Populations Most-at-Risk for HIV TAIWAN: HIV/AIDS Spreading to Younger People in Taiwan Growing HIV/AIDS awareness in Indonesia's Papua region Community-led programmes critical to progress on AIDS in Sri Lanka Civil confinement trial for NY sex offender begins CLAAD Urges FDA To End Abstinence-Only Stance On Addiction Treatment Study: AIDS Drug Cuts Infections Among Drug Users
Information in this article was accurate in September 30, 1997. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.